Philippe Reix
Université Claude Bernard Lyon 1(FR)Centre National de la Recherche Scientifique(FR)Université de Lyon(FR)Hôpital Femme Mère Enfant(FR)Hospices Civils de Lyon(FR)Hospices Civils de Lyon(FR)Laboratoire de Biométrie et Biologie Evolutive(FR)Laboratoire de Biométrie et Biologie Evolutive(FR)
Publications by Year
Research Areas
Cystic Fibrosis Research Advances, Neonatal Respiratory Health Research, Pediatric health and respiratory diseases, Tracheal and airway disorders, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Most-Cited Works
- → Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial(2017)293 cited
- → Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children(2016)234 cited
- → Lung clearance index: Evidence for use in clinical trials in cystic fibrosis(2013)181 cited
- → Severe Pulmonary Fibrosis as the First Manifestation of Interferonopathy (TMEM173 Mutation)(2016)133 cited
- → Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study(2022)129 cited
- → Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis